Kornimate/medical-research-clean huggingface dataset:
association between inflammatory activities and gap density

Conditions: Inflammatory Bowel Disease

Summary: the study aims to: 1. to determine the relationship between inflammatory activities and epithelial gaps in ibd by cle and evaluate epithelial gaps healing via dexamethasone treatment. 2. to demonstrated the alteration of local barrier function in ibd using cle.

the primary end-point of this study was the cohort comparison of epithelial gap density and local barrier function as determined by cle of subjects with ibd versus controls. despite discontinuities in the cellular layer, the intestinal barrier function is maintained during this high cell turnover rate at the apical pole of the epithelial layer. gaps first identified in vivo through acriflavine have pivotal definitions (lacked nuclei or cytosol, appeared to be filled with an impermeable substance). however, current endoscopic technology does not identify whether there is material present in human gaps, so investigators could not formally resolve whether human epithelial gaps compromise or defend the epithelial barrier.

Eligibility criteria:
inclusion criteria: * male or female aged 18-80 * ibd： patients previously diagnosed as having ibd * health control: asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy. * subjects who experienced successful intubation of the terminal ileum. exclusion criteria: * subjects age \ 80 years * subjects under conditions unsuitable for performing cle including coagulopathy (prothrombin time \ 50 s), cirrhosis, renal dysfunction (creatinine level \>1.2 mg/dl), pregnancy or breastfeeding, acute gastrointestinal bleeding, jaundice and known allergy to fluorescein sodium.

Keywords: inflammatory bowel disease confocal laser endomicroscopy
efficacy of naproxen-codeine, naproxen+dexamethasone, and naproxen on myofascial pain

Conditions: Temporomandibular Disorder

Summary: temporomandibular disorders (tmds) are one of the most common muco-skeletal disorders, seen in the dental clinics. many factors work together to initiate or aggravate the condition, so it is a multifactorial disorder. the etiology of tmds may be a result of parafunctional habits such as clenching and bruxism, acute trauma to the jaw, trauma from hyperextension e.g. after a long dental treatment, joint laxity, psychological distress, occlusal disharmony like presence of high crown or free-end saddle leading to joint instability or systemic diseases such as rheumatoid arthritis or osteoarthritis. the aim of this study was to evaluate the effects of naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, and naproxen sodium on pain in patients complaining from temporomandibular pain.


Eligibility criteria:
inclusion criteria: * without a systemic disease, * not used any medication in the last week * have a habit of clenching and / or grinding teeth, individuals with normal preoperative results, suffering with pain and / or limitation of the mouth opening in the temporomandibular region exclusion criteria: individuals who smoke * have a parafunctional habits (except for squeezing and grinding teeth) * pregnant and breastfeeding individuals * allergies to study medicines * do not use their medications / use different drugs and non-follow-up

Keywords: naproxen sodium codeine phosphate dexamethasone pain temporomandibular joint
the performance of two oxygen delivery devices used after general anesthesia.

Conditions: Hypoxemia

Summary: after general anesthesia, there are the risks for airway obstruction, hypoventilation, atelectasis, ventilation-perfusion mismatch, hypercarbia and hypoxemia,so oxygen supplement in pacu seems necessary. this study aim is to compare the two methods of oxygen supplement which are 1.nasal cannula at o2 flow 4 l/min. 2.oxygen mask with o2 flow 5 l/min. the hypothesis in this study is the 2 methods can equally provide effective oxygen supplement to prevent anesthesia-related hypoxemia. choosing nasal cannula would be reasonable because it is cheaper and more comfortable to patient.

the incidence and causes of hypoxemia in pacu will be identified, if necessary, a higher flow or changing oxygen delivery system can be used to prevent and treat hypoxemia. if any patients fail from oxygen weaning protocol in pacu and need longer oxygen therapy at ward, the duration of oxygen therapy will be recorded and also the compliance with oxygen delivery devices.

Eligibility criteria:
inclusion criteria: * general anesthesia * age 18-70 years * american society of anesthesiology (asa)physical status 1-3 * elective case exclusion criteria: * asa physical status class 4 or more * unstable pulmonary diseases * bmi \> 35 kg/m2 * oxygen saturation \< 94% when breathing in room air * respiratory muscle weakness eg.myasthenia gravis * central nervous system abnormalities eg.drowsiness, hypoventilation * patients who have been intubated or needed ventilatory support before operation * plan to remain intubated after the operation * intracranial, intrathoracic and upper abdomen surgery * patients who nasogastric tube is inserted * airway problems eg. sinusitis * nasal cavity related surgery or nasal packing eg. endoscopic sinus surgery * patient refusal

Keywords: oxygen pacu hypoxemia
micro-environment involvement in muscle alteration induced

Conditions: Chronic Obstructive Pulmonary Disease; Exacerbations; Skeletal Muscle Atrophy

Summary: chronic obstructive pulmonary disease (copd) is characterized by persistent airway obstruction and inflammatory response of the lungs and bronchi. episodes of exacerbations contribute to increase the severity and prognosis of the disease. muscle dysfunction (loss of strengh and muscle mass) is one of comorbidities affecting 30% to 60% of patients and playing a key role in their prognosis. during exacerbation, some studies have suggested an association between muscle dysfunction and modifications of inflammatory circulating factors such as crp, tnf-alpha, il- 6, il8, but no exhaustive study has identified precisely one (or more) biomarker(s) that can induce this muscle wasting during the exacerbation of copd. our hypothesis is that the serum of exacerbated copd patients represents a deleterious microenvironment for the muscle cells which would amplify the mechanisms of atrophy linked to hospitalization. our team has already developed a cell culture model to study the effects of the plasma microenvironment on atrophy of cultured myotubes. the investigators have shown that the serum of copd patients can induce muscle atrophy. the objectives of this study are : 1/ to evaluate the effects of circulating pro-inflammatory factors on atrophy and the myogenic capacities of muscle cells; and 2/ to identify one (or more) circulating biomarker (s) that may be responsible for the muscle damage induced by the microenvironment of hospitalized patients for exacerbation of copd. first, myotubes and myoblasts of healthy subjects will be cultivated with 9 exacerbation copd patient serum or 9 copd patient serum or 9 healthy subject serum. myotube diameters, atrophy, inflammatory and oxidative stress markers and alteration of the myogenic capacity of satellite cells will be compared between three groups. second, the differential expression of circulating proinflammatory molecules will be compared in the serum of the three groups. identifying circulating factors associated with muscle weakness is a necessary step to better understand the mechanisms and consider a personalized therapeutic approach that can improve the functional and clinical prognosis of disease. .


Eligibility criteria:
inclusion criteria 1/ for copd patients hospitalized for exacerbation: * hospitalization for copd exacerbation 2/ for copd patients * copd patients gold ii à iv * not having followed respiratory réhabilitation stay for at least one year 3/ for healthy subjects * healthy and sedentary (voorips score \<9) exclusion criteria: 1. for copd patients hospitalized for exacerbation: * concomitant acute cardiac évent * trachéal intubation with mechanical ventilation * chronic respiratory disease other than copd * locomotor, neurologic or psychiatric comorbidities 2. for copd patients * exacerbation with récent hospitalization (\<4 weeks) * neurologic comorbidity 3. for healthy subjects - long term drug treatment with proven central effects

Keywords: copd exacerbation muscle atrophy inflammation oxidative stress biomarkers
a randomized, blinded, multicenter study to evaluate nasha/dx for the treatment of fecal incontinence

Conditions: Fecal Incontinence

Summary: the purpose of this study is to determine the effectiveness and safety of nasha/dx when used as an injectable bulking agent in the treatment of fecal incontinence. the study includes a 6-month blinded sham-controlled phase, followed by an open-label phase.

subjects will be given up to 2 treatments of nasha/dx or sham and followed for 6 months from last treatment (ie, one retreatment is permitted at 1 month after the first injection) in the blinded phase of the study. at month 6, the open phase of the study will begin and subjects on sham will be offered open-label treatment with nasha/dx. subjects who receive nasha/dx at the start of the blinded phase will be followed for up to 36 months from last treatment in the blinded phase. subjects who receive sham at the start of the blinded phase and then receive open-label nasha/dx at month 6 (start of the open phase) will be followed for another 24 months (equivalent to approximately 30 months from randomization) from last treatment in the open phase of the study.

Eligibility criteria:
inclusion criteria: * 18-75 years of age, male or female. * screening fecal incontinence severity score (ccfis). * fecal incontinence episodes over a 14-day period. * failed conservative treatment for fecal incontinence. exclusion criteria: * complete external sphincter disruption. * significant anorectal disease. * anorectal surgery within the last 12 months prior to the study. * active inflammatory bowel disease (ibd). * immunodeficiency or receiving immunosuppressive therapy. * malignancies in remission for less than 2 years prior to the study. * bleeding disorders or receiving anticoagulant therapy. * chemotherapy within the last 12 months prior to the study. * prior pelvic radiotherapy. * women who are pregnant or breast-feeding, or women of childbearing potential not practicing adequate contraception or planning to stop such contraception within the first year of the study. * women within one year post partum. * participation in any other clinical study within 3 month prior to the study. * hypersensitivity to hyaluronic acid containing products. * other severe conditions or in other ways unsuitable to participate according to investigator judgement.
investigating the effect of chlorine dioxide and chlorhexidine mouthwash on bad breath

Conditions: Halitosis

Summary: the odor trial will be a single-centric, double-blinded, parallel-group, double-armed pilot randomized controlled trial with a non-inferiority design. the efficacy of hyperpure chlorine dioxide will be compared to chlorhexidine mouthwash. the short-term effect of the mouthwashes will be investigated in a 3-hour-long period. the primary endpoint will be the changes in the organoleptic testing scores.

eligible patients will be randomly allocated to two groups in a 1:1 ratio. necessary data will be collected with prespecified electronic case report forms (redcap). the statistician will calculate the sample size at the end of the pilot investigation of the first 30-30 patients. if feasible, investigators will continue the study by enrolling more patients.

Eligibility criteria:
inclusion criteria: * organoleptic test score (ols)\>=2 for ioh * patients with at least 20 teeth * 8 hours of scented oral hygiene product usage, 4 hours of eating, and 2 hours of drinking restriction * on the day of investigation, restriction of alcohol, caffeine, perfume usage, and food intake with characteristic smell exclusion criteria: * medical history of systematic and infectious diseases (e.g., hepatitis, hiv, tuberculosis). * antibiotic use within the month before the study's start or during the trial or any regular medication * extraoral halitosis (will be distinguished by observing the nasal breath) * eat foods (like garlic) linked to oral malodor on the day before and the sampling day, as well as wear heavily fragrant cosmetics on that day. * patients with removable dentures * smokers (cigars, cigarettes, pipes, chewing tobacco, e-cigarette, or vaping products used in the last month)

Keywords: clo2 mouth rinse malodor
impact of health lifestyle on body weight

Conditions: Body-Weight Trajectory

Summary: pharmacotherapy becomes an important and effective approach to improve body weight. however, it still remains unclear how to manage potential fluctuation after its cessation. lifestyle change is the foundation and included as a part of clinical routine in real-world, therefore, we plan to conduct a prospective observational study to assess the impact of health lifestyle along with its compliance on body weight in chinese people who live with obesity or overweight and are off-pharmacotherapy trial. the aim of this study is to examine the impact of health lifestyle along with its compliance on body weight related parameters in 6 months at 3 monthly intervals from treatment. in addition, body weight related results will be described.

novel pharmacotherapy is emerging, leading to substantial and sustained improvement in body weight compared with placebo in clinical trials. however, there is no evidence on management of body weight in real world setting after cessation of treatment. body weight fluctuation is a pivotal difficulty for obese subjects who left off pharmacotherapy. it would be interesting to investigate the impact of real-world health lifestyle and its compliance in this clinical situation and probe into factors affecting compliance. therefore, we will conduct a prospective observational study to assess the impact of health lifestyle along with its compliance on body weight in chinese people who live with obesity or overweight and are off-pharmacotherapy trial. the aim of this study is to examine the impact of health lifestyle along with its compliance on body weight related parameters in 6 months at 3 monthly intervals from pharmacotherapy cessation. in addition, body weight related results will be described.

Eligibility criteria:
inclusion criteria: * all patients who completed a pharmacotherapy trial * those who consent to this fu study exclusion criteria: * those who do not consent to this study
oral (hypo-)function, general function and nutritional status in elderly hospitalized patients

Conditions: Oral Health; Oral Health Related Quality of Life; Nutrition Disorders in Old Age

Summary: the goal of this observational study is to learn about the effects of a reduced oral function on the nutritional status of non-acute hospitalized elders and on their oral health quality of life.

malnutrition is highly prevalent among the elderly, many authors reported on the relationship between oral health and nutrition. however the the relationship between the dental state and the nutritional status was always limited to anatomical criteria such as number of teeth and the presence of prosthetic reconstructions. the oral function is classified into 4 stages healthy state, oral frailty, oral hypofunction and oral dysfunction. the classification into the different stages result from an examination of 7 parameters: the oral hygiene, the oral dryness, the occlusal force, the tongue-lip motor function, the tongue pressure, the chewing function and the swallowing function. this study aims to correlate the oral function with the nutritional status of non-acute hospitalized elders. and to further investigate the correlation between the different parameters defining the oral function and the oral health related quality of life (ohrqol) as measured by thegeneral oral health assessment index. a total 60 participants will be recruited in the university hospital of geneva, loëx rehabilitation center. the investigators will see the patient for 2 visits after informed consent. the first visit will be 45 minutes long and will include a dental examination and an examination of the oral hygiene, the oral dryness, the tongue lip motor function, the tongue pressure, the occlusal force and the swallowing function. diagnosis for nutrition according to the glim criteria will be done. furthermore, the participants will be asked to fill an oral health quality of life questionnaire comprising 12 questions. oral hypo function will be defined as a state when 3 or more signs were present from the 7 parameters examined. linear multiple regression analysis is used to examine the relationship between the nutritional status and oral function. spearman's rank correlation coefficient will be used to correlate the oral function score and oral health related quality of life.

Eligibility criteria:
inclusion criteria: * • aged 70 years or over * hospitalized in geneva university hospitals, in rehabilitation or in long term care (loëx) * able to follow simple instructions and perform the tests * understand french and complete or answer the questionnaire * give written informed consent * consent can be obtained from their next of kin or legal representative if necessary * have been admitted into the hospital no longer 15 days before inclusion exclusion criteria: * patients with tube/intravenous feeding * poorly-controlled diabetes (liu et al., 2015) * patients with gastro-intestinal diseases or symptoms (nausea, vomiting, diarrhea, constipation) affecting oral intake * if the patient is taking an antimicrobial treatment at this time.
molecular analysis of human neural stem cells

Conditions: Parkinson's Disease; Parkinsonism

Summary: the aim of this study is to develop and optimize methods to isolate, propagate and differentiate adult human neural stem cells from patients with degenerative neurological disorders like parkinson's disease.

in this project the investigators propose to analyze tissue samples from different nervous system regions obtained during neurosurgical procedures in order investigate the presence of neural stem cells in different cerebral areas. the investigators will also evaluate techniques for neural stem cell cryopreservation, for possible future therapeutic uses. patients with degenerative neurological disorders like parkinson's disease undergoing neurosurgical procedures meeting our selection criteria will be candidate for this study.

Eligibility criteria:
inclusion criteria: 1. able to give informed consent prior to study 2. male or female with diagnostic criteria of parkinson's disease or neurodegenerative disorder undergoing a neurosurgical procedure 3. age 35 to 85 years old 4. parkinson's disease not due to trauma, infection, brain tumor, cerebrovascular disease 5. hoehn and yahr stage iii or iv 6. parkinson's disease observed in the absence of: * oculomotor palsy * cerebellar sign * orthostatic hypotension (drop greater than 20mmhg in mean pressure) * pyramidal sign * amyotrophy 7. good general health or stable medical condition well controlled, without contraindications to anesthesia exclusion criteria: 1. patients with severe dementia and brain atrophy on mri 2. patients with severe hypertension; renal, liver, cardiac or other major organ disease; coagulopathy; cancer; other significant systemic illnesses; hepatitis, hiv 3. patients older than 85 or younger than 35 4. patients who withhold informed consent 5. patients with a history of alcohol or drug abuse 6. sexually active women of childbearing potential without adequate form of birth control 7. evidence of abnormal coagulation or anticoagulant therapy 8. pregnancy or lactation 9. history of seizure disorders or current use of antiepileptic medication 10. severe cognitive impairment 11. clinically significant laboratory abnormality

Keywords: parkinson's disease neural stem cells
biofeedback and hydrogen water as treatments for chronic fatigue syndrome

Conditions: Chronic Fatigue Syndrome

Summary: the aim of this 10-week pilot study is to explore the potential benefit of two recently developed non-invasive interventions, heart rate variability biofeedback (hrv-bf) and otc supplement hydrogen water, for the symptoms of chronic fatigue syndrome (cfs). symptom measures and heart monitoring information will be generated by this study. given the lack of effective treatments in this illness, these two non-invasive home-based treatments may help patients feel and function better.

the aim of this 10-week pilot study is to explore the potential benefit of two recently developed non-invasive interventions, heart rate variability biofeedback (hrv-bf) and over the counter (otc) supplement hydrogen water, for the symptoms of chronic fatigue syndrome (cfs). symptom measures and heart monitoring information will be generated by this study. given the lack of effective treatments in this illness, these two non-invasive home-based treatments may help patients feel and function better. participants will be randomized to one of the three study condition, hrv-bf alone, hydrogen water alone or combined hrv-bf and hydrogen water. all interventions are home-based with no in person visits. all communications with participants will be via virtual call, phone call, email and land mail.

Eligibility criteria:
inclusion criteria: diagnosis of chronic fatigue, chronic fatigue syndrome, or something similar. ages 18-65. - bmi\>30. exclusion criteria: * other major medical condition or regular medication that produces fatigue. no home computer or internet access. no smart phone.

Keywords: heart rhythm biofeedback; hydrogen water
prep among msm and tg in myanmar

Conditions: HIV Infections

Summary: hiv is concentrated among key populations in myanmar. globally, hiv-prevalence among transgender (tg) women is one of the highest; laboratory-confirmed prevalence is reported up to 40%. in september 2015, who recommended the use of pre-exposure prophylaxis (prep) for people at substantial risk of hiv as part of a combination hiv prevention strategy. a demonstration project will take place to implement and evaluate the uptake and effectiveness of prep among msm, and tg women in a clinic in hlaingtharyar township, yangon. the aim is to describe prep uptake, as well as hiv-seroconversion and sti infection rates among those who use prep.


Eligibility criteria:
inclusion criteria: * hiv-negative * no suspicion of acute hiv infection * substantial risk of hiv infection * creatinine clearance is more than 30 ml/min * willingness to use prep as prescribed, including periodic hiv testing * willingness to sign informed consent exclusion criteria: • anyone who is not eligible with the inclusion criteria

Keywords: pre-exposure prophylaxis of hiv infection prep msm tg